Steve Wilton

Stephen Donald Wilton , also known as Steve Wilton, is an Australian molecular biologist and academic, serving as the Foundation Professor of Molecular Therapy at Murdoch University and adjunct professor at the University of Western Australia (UWA). He also fulfills dual roles as a Director at the Perron Institute for Neurological and Translational Science and deputy director at Murdoch's Centre for Molecular Medicine and Innovative Therapeutics (CMMIT).

Wilton and his colleague Sue Fletcher were among the first to explore the application of antisense oligomers for treating Duchenne muscular dystrophy (DMD). Their research led to the development of three exon-skipping compounds that have received approval from the US FDA for restoring functional dystrophin expression in the most common mutations associated with DMD. His research in molecular therapy and translational medicine, emphasizing neuromuscular diseases like DMD, has earned him awards such as the Western Australian Innovator of the Year Award, the Australian Museum Eureka Award for Translational Medicine, and the LabGear Discovery Award. He was honored as an Officer of the Order of Australia for his contributions to medical research, neurological science, and muscular dystrophy.

Wilton holds the title of Paul Harris Fellow at Rotary International and is an Honorary Life Member of Muscular Dystrophy Western Australia and the Australasian Gene and Cell Therapy Society. Provided by Wikipedia